U.S. Markets closed
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • Dow 30

    33,800.60
    +297.03 (+0.89%)
     
  • Nasdaq

    13,900.19
    +211.39 (+1.54%)
     
  • Russell 2000

    2,243.47
    +20.42 (+0.92%)
     
  • Crude Oil

    59.34
    -0.26 (-0.44%)
     
  • Gold

    1,744.10
    -14.10 (-0.80%)
     
  • Silver

    25.33
    -0.26 (-1.02%)
     
  • EUR/USD

    1.1905
    +0.0031 (+0.2619%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • Vix

    16.69
    -0.47 (-2.74%)
     
  • GBP/USD

    1.3706
    -0.0032 (-0.2316%)
     
  • USD/JPY

    109.6500
    -0.1800 (-0.1639%)
     
  • BTC-USD

    59,723.95
    -791.89 (-1.31%)
     
  • CMC Crypto 200

    1,235.89
    +45.20 (+3.80%)
     
  • FTSE 100

    6,915.75
    +30.43 (+0.44%)
     
  • Nikkei 225

    29,768.06
    +37.26 (+0.13%)
     

Autism Pipeline Review, H2 2020 Featuring 40+ Companies - Therapeutics Development, Drug Profiles, Dormant Projects, Development Milestones - ResearchAndMarkets.com

·3 min read

The "Autism - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Autism - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 21, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  1. Introduction

  2. Autism - Overview

  3. Autism - Therapeutics Development

  4. Autism - Therapeutics Assessment

  5. Autism - Companies Involved in Therapeutics Development

  6. Autism - Drug Profiles

  7. Autism - Dormant Projects

  8. Autism - Discontinued Products

  9. Autism - Product Development Milestones

  10. Appendix

Companies Mentioned

  • 4D Pharma Plc

  • AgeneBio Inc

  • AgoneX Biopharmaceuticals Inc

  • AsiaBiome

  • Benuvia Therapeutics Inc

  • Blackthorn Therapeutics Inc

  • BrainStorm Cell Therapeutics Inc

  • Cennerv Pharma (S) Pte Ltd

  • ChunLab Inc

  • Cox Biosciences LLC

  • Curemark LLC

  • Cytocom Inc

  • Epigen Biosciences Inc

  • F. Hoffmann-La Roche Ltd

  • Finch Therapeutics Group

  • GW Pharmaceuticals Plc

  • Immuron Ltd

  • Intra-Cellular Therapies Inc

  • Johnson & Johnson

  • MD Healthcare Inc

  • Neurochlore

  • Omeros Corp

  • OptiNose US Inc

  • Oryzon Genomics SA

  • Ovensa Inc

  • Panorama Research Inc

  • Park Active Molecules

  • Reviva Pharmaceuticals Inc

  • RogCon Inc

  • Rugen Therapeutics R&D (Shanghai) Co Ltd

  • Scioto Biosciences Inc

  • Sengenics International Pte Ltd

  • Sosei Heptares

  • Stem Cell Medicine Ltd

  • Sumitomo Dainippon Pharma Co Ltd

  • Therapix Biosciences Ltd

  • Zelira Therapeutics Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rcmr1g

View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005627/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900